eFFECTOR Therapeutics, Inc. (EFTR)

NASDAQ: EFTR · IEX Real-Time Price · USD
0.435
+0.021 (5.10%)
At close: Dec 1, 2022 4:00 PM
0.430
-0.005 (-1.17%)
After-hours: Dec 1, 2022 7:55 PM EST
5.1%
Market Cap 17.59M
Revenue (ttm) 3.19M
Net Income (ttm) 5.64M
Shares Out 41.17M
EPS (ttm) 0.56
PE Ratio 0.78
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 59,226
Open 0.44
Previous Close 0.414
Day's Range 0.42 - 0.44
52-Week Range 0.385 - 9.54
Beta n/a
Analysts Buy
Price Target 7.24 (+1,564.0%)
Earnings Date Nov 14, 2022

About EFTR

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid... [Read more]

Industry Biotechnology
Founded 2012
CEO Steve Worland
Employees 12
Stock Exchange NASDAQ
Ticker Symbol EFTR
Full Company Profile

Financial Performance

In 2021, EFTR's revenue was $1.43 million, a decrease of -96.60% compared to the previous year's $42.00 million. Earnings were $15.80 million, an increase of 11.17%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for EFTR stock is "Buy." The 12-month stock price forecast is 7.24, which is an increase of 1,563.99% from the latest price.

Price Target
$7.24
(1,563.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO –

3 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for ...

1 month ago - GlobeNewsWire

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the...

Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 Topline data, including safety and viral load reduction results from all thre...

1 month ago - GlobeNewsWire

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for...

2 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET - - Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -

2 months ago - GlobeNewsWire

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment ...

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -

2 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for t...

2 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

3 months ago - GlobeNewsWire

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for ...

3 months ago - GlobeNewsWire

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: NXGLIVCTCON
5 months ago - Benzinga

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulato...

5 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Sh...

Two partial responses observed in heavily pre-treated ER+ breast cancer patients

5 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at...

Positive initial data demonstrated pharmacologically relevant exposures

6 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

6 months ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity

7 months ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for t...

8 months ago - GlobeNewsWire

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the trea...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation reg...

9 months ago - GlobeNewsWire

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient popu...

10 months ago - GlobeNewsWire

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven T...

1 year ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs)...

1 year ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

•   Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor

1 year ago - GlobeNewsWire

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today an...

1 year ago - GlobeNewsWire

eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cance...

1 year ago - Benzinga

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin...

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways

1 year ago - GlobeNewsWire